Join us for a video replay of this insightful discussion on talent management strategies, featuring an esteemed panel with diverse experience.Continue reading
Author Archive: AZBio
The Foundation for the National Institutes of Health Announces the Launch of a Public-Private Partnership to Accelerate ALS Diagnosis and Treatment
- The Foundation for the National Institutes of Health Announces the Launch of a Public-Private Partnership to Accelerate ALS Diagnosis and Treatment
- The Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS) will create the largest open data platform for ALS research
- Partnership will enable discovery and development of diagnostic tools, biomarkers, and better treatments
Managed by the FNIH, the Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS) brings together the resources and expertise of the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH), the Food and Drug Administration (FDA), Critical Path Institute (C-Path), and other stakeholders from academia, life science companies, foundations, and patient-focused groups to tackle the tremendous challenges of diagnosing, understanding, and treating the disease. AMP ALS is supported by a combined commitment of approximately $60 million.Continue reading
Nectero Medical Announces Completion of $96M Series D Financing
The proceeds will support the execution of the Phase II/III trial and potential NDA submission for the Nectero EAST System, a Breakthrough Therapy for small to medium-sized AAA.Continue reading
Accelerate Diagnostics Announces 510(k) Submission of the Accelerate Arc™ System to the FDA
Enabling rapid, automated microbial identification directly from positive blood culture samplesContinue reading
Non-Competition Agreements and the FTC
With the recent FTC Ruling Banning Non-Compete Agreements, more attention is now now focused on this long standing business practice. This educational video update on Non-Compete Agreements was hosted by AZBio and presented by Helen Holden of Spencer Fane. Continue reading
Bhattacharya named inaugural executive director of CAMI
The Center for Advanced Molecular and Immunological Therapies will be led by Deepta Bhattacharya, PhD, a renowned immunologist at the College of Medicine – Tucson.Continue reading
Rima Alameddine Named President of BD Peripheral Intervention
FRANKLIN LAKES, N.J. (May 13, 2024) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Rima Alameddine has been named worldwide president of the BD Peripheral Intervention business unit, effective today.
New BIOSECURE bill “reinforces the national security imperative of the biotechnology industry”
House lawmakers today unveiled a new draft of the BIOSECURE Act. Shortly after, BIO President and CEO, John F. Crowley, made the following statement:
“The BIOSECURE bill released in the House today reinforces the national security imperative of the biotechnology industry as a critical strategic asset of the United States of America. It highlights a key vulnerability in our global supply chain and importantly provides a reasonable timeframe for companies to decouple their reliance on China-based biomanufacturing. It ensures during this transition that important biomedical research will not be slowed and that patients will have unimpeded access to life saving medicines.Continue reading
ACA Launches New Tools to Support Arizona Small Business
New loan guarantee and technical assistance programs available for small businesses
EPA, FDA, and USDA Issue Joint Regulatory Plan for Biotechnology
WASHINGTON, May 8, 2024 – In response to President Biden’s Executive Order 14081, “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy,” the U.S. Environmental Protection Agency (EPA), the U.S. Food and Drug Administration (FDA), and the U.S. Department of Agriculture (USDA) have developed a plan to update, streamline, and clarify their regulations and oversight mechanisms for products of biotechnology.Continue reading